BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hester D, Golabi P, Paik J, Younossi I, Mishra A, Younossi ZM. Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality. J Clin Gastroenterol 2020;54:459-67. [PMID: 30672817 DOI: 10.1097/MCG.0000000000001172] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Ahn SY, Kim SB, Song IH. Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol 2020;2020:4873875. [PMID: 32566546 DOI: 10.1155/2020/4873875] [Reference Citation Analysis]
2 Aly A, Ronnebaum S, Patel D, Doleh Y, Benavente F. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepat Oncol 2020;7:HEP27. [PMID: 32774837 DOI: 10.2217/hep-2020-0024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
3 Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol 2022;28:310-31. [PMID: 35110952 DOI: 10.3748/wjg.v28.i3.310] [Reference Citation Analysis]
4 Golabi P, Rhea L, Henry L, Younossi ZM. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int. 2019;13:688-694. [PMID: 31701393 DOI: 10.1007/s12072-019-09995-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
5 Wong CR, Lim JK. Increasing contribution of non-alcoholic fatty liver disease to hepatocellular carcinoma incidence and mortality in U.S. Medicare. Hepatobiliary Surg Nutr 2019;8:506-8. [PMID: 31673540 DOI: 10.21037/hbsn.2019.04.06] [Reference Citation Analysis]
6 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
7 Patton H, Burchette R, Tovar S, Pio J, Shi J, Nyberg LM. Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT. BMC Gastroenterol 2020;20:362. [PMID: 33129272 DOI: 10.1186/s12876-020-01492-9] [Reference Citation Analysis]
8 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Younossi ZM, Yilmaz Y, Yu ML, Wai-Sun Wong V, Fernandez MC, Isakov VA, Duseja AK, Mendez-Sanchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis GV, Chan WK, Alswat K, Saeed HS, Singal AK, Romero-Gomez M, Gordon SC, Roberts SK, El Kassas M Sr, Kugelmas M, Ong JP, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01183-6. [PMID: 34768009 DOI: 10.1016/j.cgh.2021.11.004] [Reference Citation Analysis]
10 Barzi A, Zhou K, Wang S, Dodge JL, El-Khoueiry A, Setiawan VW. Etiology and Outcomes of Hepatocellular Carcinoma in an Ethnically Diverse Population: The Multiethnic Cohort. Cancers (Basel) 2021;13:3476. [PMID: 34298690 DOI: 10.3390/cancers13143476] [Reference Citation Analysis]
11 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
12 Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology 2020;72:1605-16. [PMID: 32043613 DOI: 10.1002/hep.31173] [Cited by in Crossref: 149] [Cited by in F6Publishing: 108] [Article Influence: 74.5] [Reference Citation Analysis]
13 Liu H, Xu J, Li H, Zhang L, Xu P. Network pharmacology-based investigation to explore the effect and mechanism of Erchen decoction against the nonalcoholic fatty liver disease. Anat Rec (Hoboken) 2021;304:2605-19. [PMID: 34536264 DOI: 10.1002/ar.24770] [Reference Citation Analysis]
14 Hsu JY, Liu PP, Liu AB, Huang HK, Loh CH. High 1-year risk of stroke in patients with hepatocellular carcinoma: a nationwide registry-based cohort study. Sci Rep 2021;11:10444. [PMID: 34001950 DOI: 10.1038/s41598-021-89867-0] [Reference Citation Analysis]
15 Ahmad MI, Khan MU, Kodali S, Shetty A, Bell SM, Victor D. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. JHC 2022;Volume 9:477-96. [DOI: 10.2147/jhc.s344559] [Reference Citation Analysis]
16 Kabarra K, Golabi P, Younossi ZM. Nonalcoholic steatohepatitis: global impact and clinical consequences. Endocr Connect 2021;10:R240-7. [PMID: 34486981 DOI: 10.1530/EC-21-0048] [Reference Citation Analysis]
17 Golabi P, Paik JM, Eberly K, de Avila L, Alqahtani SA, Younossi ZM. Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C. Ann Hepatol 2021;27:100556. [PMID: 34800721 DOI: 10.1016/j.aohep.2021.100556] [Reference Citation Analysis]
18 Paik JM, Henry L, De Avila L, Younossi E, Racila A, Younossi ZM. Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States. Hepatol Commun 2019;3:1459-71. [PMID: 31701070 DOI: 10.1002/hep4.1419] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
19 Xu H, Wang L. The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease. Front Mol Biosci 2021;8:792667. [PMID: 34901163 DOI: 10.3389/fmolb.2021.792667] [Reference Citation Analysis]